PUBLIC COMPANY
save$HOOKHOOKIPA Pharma Inc.
$HOOKNew York, NY, USupdated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Gubra CEO gets the quick hook; Ex-HHS official Brett Giroir takes over at cancer biotech→ AbbVie and Boehringer Ingelheim’s Danish obesity partner Gubra is going with a co-CEO arrangement after the abrupt departure of Markus Rohrwild. Endpoints News just spoke with Rohrwild last month…endpoints · 4d ago
- Windward prices $175M IPO to advance China-licensed lung drugsThe Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.biopharma_dive · 4d ago
- A new tactic in the war over out-of-network bills: Health care providers are suing employersProviders increasingly are suing employers, claiming they are responsible for out-of-network medical bills that insurers haven’t fully paid or have delayed paying.stat · 6d ago
- ‘Flying blind’: Why experts fear Treasury’s China biotech investment crackdown will backfireThe U.S. Treasury's COINS Act proposal aims to shield U.S. biotech from Chinese competition, but insiders warn it will backfire. As lawyers scramble to decipher an ambiguous ban on cross-border "jo…fiercebiotech · 10d ago
- Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdictWith companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…biospace · 15d ago
- Labor Department finalizes sweeping PBM disclosure ruleStarting in 2027, the controversial drug middlemen will have to share a broad swath of fee and compensation data with self-funded employer clients. Employers cheered the rule, while PBMs slammed it…biopharma_dive · 18d ago
- Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engagerRoche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.biospace · 25d ago
- Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slumpPlus news about United Therapeutics, Liquidia, Sanofi, Pharming, Skyhook Bio and Altay Therapeutics. Ultragenyx Pharmaceutical sells second PRV this month: The commercial-stage rare disease drugmak…endpoints · 1mo ago
- Opinion: How states can resist the potential Trump vaccine shortages“States can serve as a last line of defense against the Trump administration’s anti-vaccine policy,” writes Joel Dodge.stat · 1mo ago
- Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipelineZealand Pharma is paying Generate Biomedicines $30 million upfront to collaborate on multispecific drug candidates for metabolic diseases. Milestones could bring the total value of the deal above $…fiercebiotech · 1mo ago
Data sources
last refreshed 52m ago
Found something off?
comments(0)
5-min edit window · permanent after that